Huadong Medicine: Announcement regarding the approval notification for new drug clinical trials by the US FDA obtained by the wholly-owned subsidiary
Huadong Medicine: Announcement of the resolution of the first extraordinary Shareholders' Meeting in 2024.
Huadong Medicine: Legal Opinion of Zhejiang Tian Ce Law Firm on The First Extraordinary General Meeting of Shareholders of Huadong Medicine Co., Ltd. in 2024.
Huadong Medicine: Announcement Regarding the Reduction of Restricted Stocks Subject to Buyback and Cancellation, Decrease of Registered Capital and Notice to Creditors.
Huadong Medicine: Announcement on the adjustment of the repurchase price of restricted stocks incentive plan for the year 2022 (updated)
Huadong Medicine: Independent financial advisor report on the adjustment of repurchase price and repurchase cancellation of some restricted stocks in the 2022 restricted stock incentive plan of huadong medicine limited by GuoSheng Securities Co., Ltd.
Huadong Medicine: Announcement regarding expanding the scope of operation, changing registered capital, and revising the "Articles of Association" (updated).
Huadong Medicine: Legal Opinion of Zhejiang TianCe Law Firm on the Adjustment of Restricted Stock Grant Price and Redemption and Cancellation of Restricted Stocks of Huadong Medicine Co., Ltd.'s Restricted Stock Incentive Plan for 2022.
Huadong Medicine: Correction announcement regarding the repurchase and cancellation of restricted stocks.
Huadong Medicine: Announcement Regarding Repurchasing and Cancelling Certain Restricted Stocks (Updated)
Huadong Medicine: The supervisory board's verification opinion on the adjustment of the 2022 restricted stock incentive plan repurchase price and repurchase cancellation of some restricted stocks (updated).
Huadong Medicine: Q1 report in 2024 (English version)
Huadong Medicine: 2023 Annual Report (English Version)
Huadong Medicine: Announcement Regarding Full Subsidiary Obtaining Approval Notice for Clinical Trials of Drugs.
Huadong Medicine: Announcement on the Adjustment of Restricted Stock Incentive Plan Repurchase Price for 2022 (Before Update)
Huadong Medicine: Legal Opinion of Zhejiang Tianze Law Firm on Huadong Pharmaceutical Co., Ltd.'s 2022 Restricted Stock Incentive Plan to Adjust Restricted Stock Repurchase Prices and Repurchase and Cancellation of Some Restricted Shares
Huadong Medicine: Announcement of Resolutions of the 16th Meeting of the 10th Board of Supervisors
Huadong Medicine: The Supervisory Board's verification opinion on the adjustment of the repurchase price and cancellation of restricted stocks of the 2022 restricted stock incentive plan (pre-update).
Huadong Medicine: Independent Financial Advisory Report of Guosheng Securities Co., Ltd. on the 2022 Restricted Stock Incentive Plan of Huadong Pharmaceutical Co., Ltd. on the adjustment of repurchase prices and the repurchase and cancellation of some restricted stocks
Huadong Medicine: Announcement on the Proposed Repurchase and Cancellation of Restricted Stocks (pre-update)
No Data